Served as CEO for rare disease company positioned to be spun out of Array BioPharma, sponsored by Redmile group. Raised $60+ million in equity financing to support spin out into independent company. Lead program was entering Phase 3 for genetically defined rare disease. Programs were ultimately retained by Array.

President and CEO: 2017President: 2015- 2016Biopharmaceutical company focused on the development and commercialization of therapeutics for rare and severe diseases with high unmet medical needs.

Led Business Development, Commercial, Corporate Finance (IPO, crossover financings, company sale), Corporate Strategy and Portfolio management functions for biopharmaceutical company developing innovative therapeutics for severe diseases within CNS and Respiratory therapeutic areas. Company was backed by leading life science venture capital firms and public crossover investors. Sold to Acorda Therapeutics in 2014.

Led Corporate Development, Business Development and Corporate Strategy functions for biopharmaceutical company focused on developing and commercializing therapeutics targeting the acute care hospital market. Company was backed by leading life science venture capital firms. Sold to Cheisi in 2012.

Led Business Development, Corporate Development, Corporate Strategy and Corporate Finance (including company sale) functions for biopharmaceutical company focused on developing and commercializing therapeutics for rare and severe diseases. Portfolio included Xenazine (Huntington's Disease), Sabril (infantile spasms) and Onfi (Lennox-Gastaut Syndrome). Sold to Lundbeck A/S in 2009.